ArticleBiochemical pharmacology2013
Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities.
Article in Biochemical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Association between pesticide exposure and colorectal cancer risk and incidence: A systematic review.Ecotoxicology and environmental safety · 2021Pooled it
- Genetic Dereplication of MultipleJournal of natural products · 2026Article
- Paraisariamides: Cycloheptapeptide Toxins from Entomopathogenic Fungi (Journal of natural products · 2026Article
- Discovery of a fungal Tc toxin complex and functional mycoserpin through a novel two-by-two comparative genomics approach.Frontiers in cellular and infection microbiology · 2026Article
- Marine-derived Acremonium strain prioritization using untargeted metabolomics approach for the identification of cytotoxic cyclic depsipeptides.BMC biotechnology · 2025Article
- Inducible mismatch repair streamlines forward genetic approaches to target identification of cytotoxic small molecules.Cell chemical biology · 2023Article
- In Vitro Efficacy of Extracts and Isolated Bioactive Compounds from Ascomycota Fungi in the Treatment of Colorectal Cancer: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Fungal Guttation, a Source of Bioactive Compounds, and Its Ecological Role-A Review.Biomolecules · 2021Review
- Destruxin A Interacts with Aminoacyl tRNA Synthases inJournal of fungi (Basel, Switzerland) · 2021Article
- Cyclodepsipeptides and Sesquiterpenes from Marine-Derived FungusMarine drugs · 2018Article
- Article
- Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.Oncotarget · 2018Article
- Two cyclic hexapeptides from Penicillium sp. FN070315 with antiangiogenic activities.PloS one · 2017Article
- Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling.Oncotarget · 2016Article
- EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.Journal of experimental & clinical cancer research : CR · 2015Article
- The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.Biochemical pharmacology · 2015Article
- Selective apoptotic cell death effects of oral cancer cells treated with destruxin B.BMC complementary and alternative medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Destruxins (Dtx) are secondary metabolites of the entomopathogenic fungus Metarhizium anisopliae. Recently, Dtx came into focus of interest as anticancer therapeutics. However, data on human and especially on cancer cells are fragmentary. In order to successfully establish novel anticancer therapeutics, a broad knowledge on the cellular and molecular mechanisms underlying their activity is essential. Consequently, this study aimed to investigate the impact of the most common Dtx derivatives A, B and E on human cancer cell growth and survival with a focus on colon cancer cell models. Summarizing, the experimental data showed that (i) Dtx A and B exert potent antiproliferative activity in the micromolar and Dtx E in the nanomolar range in KB-3-1, A549, CaCo-2, and especially in HCT116 colon cancer cells, (ii) all three Dtx derivatives cause imbalance of cell cycle distribution, (iii) their cytostatic/cytotoxic effects are widely p53-independent but reduced by p21- and bax-deletion, respectively, (iv) cytotoxicity is based on intrinsic apoptosis induction and associated with phosphoinositide-3-kinase (PI3K)/Akt pathway inhibition, (v) anticancer activity of Dtx E but not Dtx A and B involves disturbance of the intracellular redox balance, (vi) Dtx inhibit the migration and tube formation of human endothelial cells indicating antiangiogenic potential, and (vii) all three Dtx derivatives possess ionophoric properties not differing in conductivity, ion selectivity and single channel kinetics. Thus, Dtx represent feasible, multifunctional anticancer drug candidates for preclinical development especially against colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.